Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Nuhoğlu Kantarcı E., Tolgay E., EŞKAZAN A. E.

Cancer, cilt.129, sa.17, ss.2610-2612, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 129 Sayı: 17
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1002/cncr.34938
  • Dergi Adı: Cancer
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Public Affairs Index, Veterinary Science Database
  • Sayfa Sayıları: ss.2610-2612
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic-phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient-based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.